{"id":125,"date":"2021-07-08T09:46:26","date_gmt":"2021-07-08T09:46:26","guid":{"rendered":"https:\/\/isosolution-v2.staging.xiyx.ai\/news\/https-isosolutions-com-wp-content-uploads-2021-07-psma-11-pet_ct-versus-choline-pet_ct-pdf\/"},"modified":"2026-09-04T19:48:39","modified_gmt":"2026-09-04T19:48:39","slug":"https-isosolutions-com-wp-content-uploads-2021-07-psma-11-pet_ct-versus-choline-pet_ct-pdf","status":"publish","type":"iso_news","link":"https:\/\/isosolution-v2.staging.xiyx.ai\/zh\/news\/https-isosolutions-com-wp-content-uploads-2021-07-psma-11-pet_ct-versus-choline-pet_ct-pdf\/","title":{"rendered":"PSMA-11-PET\/CT \u4e0e\u80c6\u78b1-PET\/CT \u7528\u4e8e\u6307\u5bfc\u5bf9\u524d\u5217\u817a\u764c\u60a3\u8005\u7684\u7acb\u4f53\u75c5\u6027\u653e\u5c04\u7597\u6cd5"},"content":{"rendered":"<p><strong>\u7b80\u8baf<\/strong><\/p>\n<p>\u80cc\u666f:\u5728\u91cd\u53d1\u6027\u524d\u5217\u817a\u764c\u5be1\u5934\u7624\u60a3\u8005\u4e2d,\u6807\u51c6\u6cbb\u7597\u662f\u65e0\u8272\u7d20\u7597\u6cd5\u3002 \u7136\u800c,ADT\u5177\u6709\u8bb8\u591a\u6f5c\u5728\u7684\u526f\u4f5c\u7528,\u53ef\u80fd\u5bfc\u81f4\u751f\u6d3b\u8d28\u91cf\u53d7\u635f\u3002 \u53ca\u65e9\u786e\u5b9a\u54ea\u4e9b\u60a3\u8005\u9002\u5408\u8fdb\u884c\u7acb\u4f53\u7597\u7a0b(SABR),\u5bf9\u4e8e\u9632\u6b62\u6216\u63a8\u8fdf\u542f\u52a8ADT\u53ca\u5176\u526f\u4f5c\u7528\u81f3\u5173\u91cd\u8981. <\/p>\n<\/p>\n<p>\u7531\u4e8e\u524d\u5217\u817a-\u7279\u5b9a\u819c-\u6297\u539f-11-\u805a\u6c28\u916f\u6392\u653e\u6258\u59c6\u5b66(PSMA-11-PET)\u7684\u7075\u654f\u5ea6\u9ad8\u4e8e\u80c6\u78b1-PET,\u56e0\u6b64\u6211\u4eec\u5047\u8bbePSMA-11-PET\u57fa\u4e8eSABR\u7684\u7ed3\u679c\u662f\u53cd\u5e94\u65f6\u95f4\u66f4\u957f,\u968f\u540e\u542f\u52a8ADT\u7684\u65f6\u95f4\u4e5f\u6bd4\u80c6\u78b1-PET\u66f4\u957f.<\/p>\n<p><strong>\u65b9\u6cd5 <\/strong><\/p>\n<p>Patients with oligometastatic (\u22644 metastases) recurrent prostate cancer (with no local recurrence) based on PSMA-11-PET or choline-PET treated with SABR from January 2012 until December 2017 were included. Primary endpoint was ADT-free survival. Secondary endpoints were Prostate Specific Antigen (PSA) response after SABR and time to PSA rise after SABR.<br \/>\u7ed3\u679c:\u5305\u62ec50\u540d\u75c5\u4eba(n = 40 PSMA-11-PET\u548cn = 10 \u80c6\u78b1-PET),\u5171\u8ba172\u6b21\u635f\u4f24\u3002 \u4e2d\u95f4\u540e\u7eed\u884c\u52a8\u4e3a24.3\u4e2a\u6708\u3002 PSMA-11-PET\u4f7fPSA\u6c34\u5e73\u4f4e\u4e8e\u80c6\u78b1\u916f\u9176-PET\u7684\u60a3\u8005\u83b7\u5f97\u4e86\u8d44\u683c(\u4e2d\u95f4\u503c1.8\u5bf94.2\u7eb3\u514b\/\u6beb\u5347,p=0.03)\u3002 PSMA-11-PET\u5c0f\u7ec4\u7684PSA\u54cd\u5e94\u65f6\u95f4\u957f\u5f97\u591a(\u4e2d\u4f4d\u657034.0\u4e2a\u6708(95% \u7f6e\u4fe1\u95f4\u9694(CI),16.0\u201352.0),\u5bf914.7\u4e2a\u6708(95% CI 4.7\u201324.7),p=0.04),\u968f\u540eADT\u65e0\u751f\u5b58\u65f6\u95f4\u957f(\u4e2d\u4f4d\u657032.7\u4e2a\u6708(95% CI,20.8\u201344.5),\u5bf914.9\u4e2a\u6708(95% CI,5.7\u201324.1),p=0.01).<\/p>\n<\/p>\n<p class=\"has-text-align-center\">\n<\/p>\n<p><strong>\u7ed3 \u8bba<\/strong><\/p>\n<p>\u6709\u4e86PSMA-11-PET,\u6211\u4eec\u5c31\u53ef\u4ee5\u5728\u66f4\u65e9\u7684\u75be\u75c5\u9636\u6bb5,\u5728\u4f4ePSA\u6c34\u5e73\u4e0a\u9009\u62e9\u9002\u5408SABR\u7684\u5be1\u805a\u6c28\u916f\u590d\u53d1\u6027\u524d\u5217\u817a\u764c\u60a3\u8005\u3002 PSMA-11-PET\u5236\u5bfc\u7684SABR\u5bfc\u81f4\u4e0e\u80c6\u78b1-PET\u76f8\u6bd4\u53cd\u5e94\u65f6\u95f4\u548cADT\u65e0\u751f\u5b58\u80fd\u529b\u663e\u8457\u5ef6\u957f,\u56e0\u6b64\u53ef\u4ee5\u9632\u6b62\u6216\u5ef6\u8fdfADT\u76f8\u5173\u526f\u4f5c\u7528.<\/p>\n<p><a href=\"https:\/\/www.ctro.science\/action\/showPdf?pii=S2405-6308%2821%2900061-6\" data-type=\"URL\"><\/a><a rel=\"noreferrer noopener\" href=\"https:\/\/www.ctro.science\/action\/showPdf?pii=S2405-6308%2821%2900061-6\" data-type=\"URL\" data-id=\"https:\/\/www.ctro.science\/action\/showPdf?pii=S2405-6308%2821%2900061-6\" target=\"_blank\">\u8bfb\u53d6 <\/a><a href=\"https:\/\/www.ctro.science\/action\/showPdf?pii=S2405-6308%2821%2900061-6\" data-type=\"URL\" data-id=\"https:\/\/www.ctro.science\/action\/showPdf?pii=S2405-6308%2821%2900061-6\">\u8054\u5408\u56fd <\/a><a rel=\"noreferrer noopener\" href=\"https:\/\/www.ctro.science\/action\/showPdf?pii=S2405-6308%2821%2900061-6\" data-type=\"URL\" data-id=\"https:\/\/www.ctro.science\/action\/showPdf?pii=S2405-6308%2821%2900061-6\" target=\"_blank\">\u6ee1 <\/a><a href=\"https:\/\/isosolutions.com\/wp-content\/uploads\/2021\/07\/PSMA-11-PET_CT-versus-choline-PET_CT.pdf\" data-type=\"URL\" data-id=\"https:\/\/isosolutions.com\/wp-content\/uploads\/2021\/07\/PSMA-11-PET_CT-versus-choline-PET_CT.pdf\">\u6761\u6b3e<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>ABSTRACT Background: In patients with oligometastatic recurrent prostate cancer, standard treatment is androgen deprivation therapy (ADT). However, ADT has many potential side effects that may result in impaired quality of life. Early identification to select patients suitable for stereotactic ablat<\/p>","protected":false},"featured_media":126,"template":"","iso_news_section":[43],"class_list":["post-125","iso_news","type-iso_news","status-publish","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/zh\/wp-json\/wp\/v2\/iso_news\/125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/zh\/wp-json\/wp\/v2\/iso_news"}],"about":[{"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/zh\/wp-json\/wp\/v2\/types\/iso_news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/zh\/wp-json\/wp\/v2\/media\/126"}],"wp:attachment":[{"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/zh\/wp-json\/wp\/v2\/media?parent=125"}],"wp:term":[{"taxonomy":"iso_news_section","embeddable":true,"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/zh\/wp-json\/wp\/v2\/iso_news_section?post=125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}